ProQR Therapeutics (PRQR) FCF Margin (2021 - 2026)
ProQR Therapeutics (PRQR) posted FCF Margin of 572.01% for Q1 2026, down 60.89% sequentially from 355.52% in Q4 2025, and down 20467.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
ProQR Therapeutics (PRQR) FCF Margin (2021 - 2026) Analysis & Trends
ProQR Therapeutics has reported FCF Margin for 14 years, with the latest figure at 572.01% in Q1 2026.
- Quarterly FCF Margin fell 20467.0% year-over-year to 572.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 391.32% (down 16157.0% YoY) and the FY2025 annual result came in at 349.6%, down 13543.0% from the prior year.
- FCF Margin eased to 572.01% in Q1 2026 per PRQR's latest filing, from 355.52% in the prior quarter.
- Over five years, FCF Margin peaked at 6821.53% in Q1 2023 and troughed at 2675.28% in Q4 2022.
- A 5-year average of 336.23% and a median of 367.34% in 2025 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2024: FCF Margin surged 865436 bps in 2023, then plunged 714512 bps in 2024.
- Over 5 years, FCF Margin stood at 2675.28% in 2022, then jumped by 93 bps to 173.93% in 2023, then plunged by 97 bps to 341.98% in 2024, then decreased by 4 bps to 355.52% in 2025, then plunged by 61 bps to 572.01% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 572.01%, 355.52%, and 418.67% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | ProQR Therapeutics | 218.57 Mn | 82.18 Mn | - | -136.76% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -136.76% |
| Mar 31, 2026 | -540.14% |
| Dec 31, 2025 | -268.32% |
| Sep 30, 2025 | -418.67% |
| Jun 30, 2025 | -296.04% |
| Mar 31, 2025 | -344.63% |
| Dec 31, 2024 | -213.95% |
| Sep 30, 2024 | -139.76% |
| Jun 30, 2024 | -94.99% |
| Mar 31, 2024 | -323.60% |
| Dec 31, 2023 | -143.73% |
| Sep 30, 2023 | -523.28% |
| Jun 30, 2023 | -834.27% |
| Mar 31, 2023 | 6,849.01% |
| Dec 31, 2022 | -2,478.61% |
| Sep 30, 2022 | -1,857.25% |
| Jun 30, 2022 | -1,571.29% |
| Mar 31, 2022 | -1,789.65% |
| Dec 31, 2021 | 1,677.82% |
| Sep 30, 2021 | -903.90% |